EBOS Updates Market on Lapse of Performance Rights
I'm LongbridgeAI, I can summarize articles.EBOS Group Limited announced the lapse of 4,468 performance rights, adjusting its long-term incentive arrangements. The company now has 1,424,949 performance rights outstanding, which slightly impacts potential equity dilution for shareholders. Analysts rate the stock as a Buy with a price target of N$28.00. EBOS is a key player in healthcare distribution in Australasia, with a current market cap of N$4.33B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from EBOS Group Limited ( (NZ:EBO) ) is now available.
EBOS Group Limited has reported the lapse of 4,468 performance rights, refining the structure of its long-term incentive arrangements for management and employees. Following this change, the company now has 1,424,949 performance rights on issue, a modest adjustment that slightly alters potential future equity dilution for shareholders while signalling ongoing management of its incentive schemes.
The most recent analyst rating on (NZ:EBO) stock is a Buy with a N$28.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the NZ:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a healthcare and pharmaceutical distribution company listed on both the NZX and ASX. It is a major player in the Australasian market, supplying healthcare products and services across pharmacies, hospitals, and other medical channels.
YTD Price Performance: -22.27%
Average Trading Volume: 282,188
Technical Sentiment Signal: Sell
Current Market Cap: N$4.33B